Analyst Ratings For G1 Therapeutics (NASDAQ:GTHX)
Today, JPMorgan Chase & Co. raised its price target on G1 Therapeutics (NASDAQ:GTHX) to per share.
Some recent analyst ratings include
- 12/19/2017-BTIG Research initiated coverage with a Buy rating.
- 11/8/2017-Cowen Reiterated Rating of Buy.
- 6/12/2017-Wedbush initiated coverage with a Outperform rating.
- 6/12/2017-Needham & Company LLC initiated coverage with a Buy rating.
- On 1/16/2018 Rajesh Malik, Insider, sold 3,776 with an average share price of $22.96 per share and the total transaction amounting to $86,696.96.
- On 1/5/2018 Jennifer K Moses, VP, sold 750 with an average share price of $19.96 per share and the total transaction amounting to $14,970.00.
- On 12/18/2017 Mark A Velleca, Insider, sold 7,500 with an average share price of $20.01 per share and the total transaction amounting to $150,075.00.
- On 12/15/2017 Medimmune Ventures, Inc., Major Shareholder, sold 200,000 with an average share price of $19.75 per share and the total transaction amounting to $3,950,000.00.
- On 12/1/2017 Medimmune Ventures, Inc., Major Shareholder, sold 133,906 with an average share price of $19.75 per share and the total transaction amounting to $2,644,643.50.
- On 11/20/2017 Medimmune Ventures, Inc., Major Shareholder, sold 200,000 with an average share price of $20.01 per share and the total transaction amounting to $4,002,000.00.
- On 11/13/2017 Fredric N Eshelman, Director, bought 250,000 with an average share price of $19.73 per share and the total transaction amounting to $4,932,500.00.
Recent Trading Activity for G1 Therapeutics (NASDAQ:GTHX)
Shares of G1 Therapeutics closed the previous trading session at with shares trading hands.